Last reviewed: April 2026 · For research use only · Not for human consumption
The GLP-1 class of incretin-based research peptides has moved from a single-receptor monotherapy paradigm (liraglutide, semaglutide) to dual incretin agonism (tirzepatide) and, most recently, to triple receptor agonism combining GLP-1R, GIPR and glucagon receptor (GCGR) activity (retatrutide). This hub consolidates the UK-focused research picture across the full class — receptor biology, Phase 2/3 trial signal strength, head-to-head weight-loss and glycaemic data, HPLC purity expectations for laboratory procurement, and UK regulatory positioning for research-only material.
What counts as a “GLP-1 peptide” in 2026 research?
GLP-1 (glucagon-like peptide-1) is a 30/31-amino-acid incretin hormone cleaved from proglucagon in intestinal L-cells. Native GLP-1 has a half-life of roughly 1–2 minutes due to rapid inactivation by dipeptidyl peptidase-4 (DPP-4). The “GLP-1 peptide” category in contemporary research therefore refers primarily to DPP-4-resistant analogues engineered with fatty-acid acylation, amino-acid substitutions at position 2 (Aib in semaglutide, tirzepatide and retatrutide), and other structural modifications that extend half-life to 12 hours (liraglutide), ~7 days (semaglutide, tirzepatide, retatrutide) and enable once-weekly dosing protocols in in vivo research models.
The class now spans four mechanistic tiers:
- GLP-1 monotherapy — liraglutide (daily), semaglutide (weekly). GLP-1R-only agonism.
- Dual GLP-1R/GIPR incretin co-agonism — tirzepatide (weekly). Adds glucose-dependent insulinotropic polypeptide receptor activation.
- Triple GLP-1R/GIPR/GCGR agonism — retatrutide (weekly). Adds glucagon receptor activation driving hepatic lipolysis and thermogenesis.
- Next-generation non-peptide and oral agonists — orforglipron (oral small molecule), CagriSema (amylin + semaglutide co-formulation), still in trial-readout phase.
Head-to-head: weight-loss signal strength in recent trials
The following weight-loss figures reflect peer-reviewed Phase 2 and Phase 3 readouts and are provided for research-context comparison only — not as treatment guidance:
| Peptide | Mechanism | Peak Dose (research) | Weight-Loss Signal (Phase 2/3) | Trial Duration |
|---|---|---|---|---|
| Liraglutide | GLP-1R mono (daily) | 3.0 mg/day | ~5.4% | 56 weeks |
| Semaglutide | GLP-1R mono (weekly) | 2.4 mg/week | ~14.9% | 68 weeks |
| Tirzepatide | GLP-1R + GIPR | 15 mg/week | ~20.9% | 72 weeks |
| Retatrutide | GLP-1R + GIPR + GCGR | 12 mg/week | ~24.2% | 48 weeks |
The trajectory is clear: each additional receptor mechanism stacks adjunctive weight-loss signal. Retatrutide delivers approximately 24.2% mean total body weight reduction at 48 weeks — the largest signal observed in any incretin-class trial to date — while tirzepatide remains the most mature dual-incretin platform with 72-week readouts available.
Receptor mechanism explained
GLP-1 receptor (GLP-1R)
A class B G-protein-coupled receptor expressed on pancreatic beta cells, hypothalamic neurons (arcuate and paraventricular nuclei), gastric smooth muscle and myocardium. Activation drives glucose-dependent insulin secretion, glucagon suppression at supraphysiologic glucose, gastric emptying delay and hypothalamic satiety signalling. GLP-1R activation is the central mechanism shared by all peptides in this hub.
GIP receptor (GIPR)
Added by tirzepatide and retatrutide. GIPR activation in adipose tissue promotes buffering capacity for postprandial triglycerides, and in beta cells potentiates insulin secretion synergistically with GLP-1R. GIPR agonism appears to blunt GLP-1-class nausea pharmacology — a tolerability feature visible in tirzepatide trial dropout rates.
Glucagon receptor (GCGR)
Added only by retatrutide. GCGR activation at the liver increases hepatic lipolysis, fatty acid oxidation, and basal metabolic rate through thermogenesis. The triple-agonist net effect adds an energy-expenditure arm to the classical incretin (energy-intake suppression) pharmacology — explaining retatrutide’s weight-loss signal exceeding dual agonism at lower absolute dose.
For the complete receptor biology, binding affinity ratios and downstream cAMP/PKA signalling detail across the triagonist platform, read our Retatrutide UK Complete Research Guide 2026.
UK research procurement: purity and sourcing
For in vivo metabolic research, incretin-class peptides must meet the following quality specifications to yield reproducible receptor pharmacology data:
- HPLC purity ≥99% — analytical HPLC (RP-C18, UV 215 nm) with chromatogram per batch. Purities below 99% introduce receptor desensitisation artefacts from deletion-sequence and oxidation impurities.
- Mass spectrometry confirmation — ESI-MS or MALDI-TOF exact-mass verification matching theoretical molecular weight within ≤1 Da.
- Batch-specific Certificate of Analysis (COA) — date-stamped, batch-numbered, not generic marketing documents. COA should include peptide content by TFA salt correction, water content, endotoxin if lyophilised.
- Cold-chain lyophilisation and shipping — incretin peptides are moisture-sensitive; loose-packed powder without desiccant is a red flag. UK-dispatched stock should ship with gel packs for reconstituted material.
For a detailed procurement protocol covering reconstitution, storage half-life, supplier due diligence and the specific UK research-context caveats, see Retatrutide Research: Dosage Protocols, HPLC Sourcing & UK Compliance Guide 2026.
UK regulatory positioning
In the United Kingdom, the incretin-class peptides discussed here are not authorised as research-use-only products by the MHRA for any purpose outside licensed medicinal preparations. Products sold on the UK market as research peptides — including retatrutide, tirzepatide and non-formulated semaglutide — are supplied strictly for in vitro and laboratory animal research under a research-use-only (RUO) designation, are not sterile-filtered pharmaceutical preparations, and are not intended, labelled or supplied for human consumption. Procurement by UK research laboratories should follow standard controlled-substances logging, COSHH risk assessment and ethical-committee oversight where animal work is involved.
Which GLP-1 peptide for which research question?
The choice of molecule depends on the mechanism being tested, not simply weight-loss magnitude:
- Isolated GLP-1R biology → semaglutide (weekly) or liraglutide (daily) for time-course flexibility.
- Incretin synergy / GIPR adipose biology → tirzepatide. See our Tirzepatide UK Complete Research Guide.
- Thermogenesis / hepatic lipolysis / energy-expenditure research → retatrutide. See the Retatrutide UK Guide.
- Head-to-head dual-vs-triple comparison → read Tirzepatide vs Retatrutide for Weight-Loss Research UK.
- Triple vs mono baseline → read Retatrutide vs GLP-1 Monotherapy Research UK.
Related UK research pillars
- Retatrutide UK: Complete Research Guide 2026 — triple agonism, Phase 2 readouts, dosage protocols
- Tirzepatide UK: Complete Research Guide 2026 — dual incretin, SURMOUNT data, GIPR biology
- Best Peptides for Type 2 Diabetes Research UK — beta-cell biology, glucotoxicity
- Best Peptides for Metabolic Syndrome Research UK — visceral adiposity, AMPK signalling
- Peptides UK: Research-Grade Sourcing Guide — the site-wide UK procurement hub
Buy research-grade GLP-1 class peptides in the UK
Peptides Lab UK supplies the full GLP-1 research-peptide class, HPLC-tested to ≥99% purity with mass-spec confirmation and batch-specific COA, UK-dispatched:
- Retatrutide — triple GLP-1R/GIPR/GCGR agonist
- Tirzepatide — dual GLP-1R/GIPR incretin co-agonist
- Semaglutide — weekly GLP-1 monotherapy
UK Research Cluster Hubs
The GLP-1 class sits inside a broader UK research peptide ecosystem. Explore the canonical pillars and sourcing hubs:
- Retatrutide UK: Complete Research Guide 2026 — triple-agonist (GLP-1R / GIPR / GCGR) pillar
- Tirzepatide UK: Complete Research Guide 2026 — dual GLP-1R/GIPR incretin pillar
- BPC-157 UK: Complete Research Guide 2026 — pentadecapeptide tissue-repair pillar
- TB-500 UK: Complete Research Guide 2026 — thymosin beta-4 actin-biology pillar
- Peptides UK: Research-Grade Sourcing Guide — site-wide UK procurement hub
- Buy Research Peptides UK: HPLC, COA & Supplier Due-Diligence Guide — verify purity and a legitimate UK supplier
Frequently Asked Questions
What is the difference between a dual and triple GLP-1 agonist?
A dual GLP-1 agonist (tirzepatide) activates both the GLP-1 and GIP receptors. A triple GLP-1 agonist (retatrutide) additionally activates the glucagon receptor (GCGR), adding hepatic lipolysis and thermogenesis to the classical incretin mechanism and producing the largest weight-loss signal observed in the class to date.
Which GLP-1 peptide produces the largest weight-loss signal in research?
Retatrutide currently produces the largest Phase 2 weight-loss signal at approximately 24.2% mean total body weight reduction over 48 weeks at the 12 mg weekly dose. Tirzepatide follows at approximately 20.9% at 15 mg weekly over 72 weeks. Semaglutide produces approximately 14.9% at 2.4 mg weekly over 68 weeks.
Are GLP-1 research peptides legal to buy in the UK?
GLP-1 class research peptides such as retatrutide, tirzepatide and non-formulated semaglutide can be procured in the UK strictly for in vitro and laboratory animal research use, sold under a research-use-only designation and not as licensed medicinal products. They are not authorised, labelled or supplied for human consumption. Licensed medicinal preparations (e.g. Wegovy, Mounjaro) are separate regulated products dispensed by prescription.
What HPLC purity should I require from a UK GLP-1 peptide supplier?
Research-grade GLP-1 class peptides should be supplied at HPLC purity of ≥99% with a batch-specific Certificate of Analysis, mass-spectrometry confirmation of the exact molecular weight, and documented peptide content corrected for trifluoroacetate salt.
Which GLP-1 peptide is best for type 2 diabetes research?
The choice depends on the research question. Semaglutide provides the cleanest single-receptor GLP-1R pharmacology. Tirzepatide is preferred for studies probing incretin synergy and GIPR adipose biology. Retatrutide is used where the GCGR-mediated hepatic glucose output arm is relevant.
Can I use retatrutide and tirzepatide interchangeably in research?
No. They are mechanistically distinct. Tirzepatide is a dual GLP-1R/GIPR agonist with no glucagon receptor activity. Retatrutide adds GCGR agonism, introducing hepatic lipolysis, fatty-acid oxidation and thermogenic signalling absent from tirzepatide pharmacology. Swapping the two confounds receptor-specific interpretations.
